Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 10, 2009 - Issue 15
Submit an article Journal homepage
378
Views
18
CrossRef citations to date
0
Altmetric
Reviews

Atypical antipsychotics in the elderly: a review of therapeutic trends and clinical outcomes

Anna D Burke Banner Alzheimer's Institute, 901 E Willetta Street, Phoenix, AZ 85006, USA +1 602 239 6967; +1 602 239 6906; [email protected]
, MD &
Pierre N Tariot Banner Alzheimer's Institute, 901 E Willetta Street, Phoenix, AZ 85006, USA +1 602 239 6967; +1 602 239 6906; [email protected]
, MD
Pages 2407-2414 | Published online: 11 Aug 2009

Bibliography

  • Losonczy KG, White LR, Brock DB. Prevalence and correlates of dementia: survey of the last days of life. Public Health Rep 1998;113(3):273-80
  • Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000;157(5):708-14
  • Testad I, Aasland AM, Aarsland D. Prevalence and correlates of disruptive behavior in patients in Norwegian nursing homes. Int J Geriatr Psychiatry 2007;22(9):916-21
  • Zuidema SU, van der Meer MM, Pennings GA, Koopmans RT. Prevalence of behavioural problems in a group of demented nursing home patients. Tijdschr Gerontol Geriatr 2006;37(1):19-24
  • Brodaty H, Low LF. Aggression in the elderly [review]. J Clin Psychiatry 2003;64(Suppl 4):36-43
  • Tractenberg RE, Weiner MF, Patterson MB, et al. Comorbidity of psychopathological domains in community-dwelling persons with Alzheimer's disease. J Geriatr Psychiatry Neurol 2003;16(2):94-9
  • Ryu SH, Katona C, Rive B, Livingston G. Persistence of and changes in neuropsychiatric symptoms in Alzheimer disease over 6 months: the LASER-AD study. Am J Geriatr Psychiatry 2005;13(11):976-83
  • Matsui T, Nakaaki S, Murata Y, et al. Determinants of the quality of life in Alzheimer's disease patients as assessed by the Japanese version of the quality of life-Alzheimer's disease scale. Dement Geriatr Cogn Disord 2006;21(3):182-91
  • Banerjee S, Smith SC, Lamping DL, et al. Quality of life in dementia: more than just cognition. An analysis of associations with quality of life in dementia. J Neurol Neurosurg Psychiatry 2006;77(2):146-8
  • Drevets WC, Rubin EH. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biol Psychiatry 1989;25(1):39-48
  • Rosen J, Zubenko GS. Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease. Biol Psychiatry 1991;29(3):224-32
  • Wilson RS, Tang Y, Aggarwal NT, et al. Hallucinations, cognitive decline, and death in Alzheimer's disease. Neuroepidemiology 2006;26(2):68-75
  • Walsh JS, Welch HG, Larson EB. Survival of outpatients with Alzheimer-type dementia. Ann Intern Med 1990;113(6):429-34
  • Allen RS, Burgio LD, Fisher SE, et al. Behavioral characteristics of agitated nursing home residents with dementia at the end of life. Gerontologist 2005;45(5):661-6
  • Bowen JD, Malter AD, Sheppard L, et al. Predictors of mortality in patients diagnosed with probable Alzheimer's disease. Neurology 1996;47(2):433-9
  • Samson WN, van Duijn CM, Hop WC, Hofman A. Clinical features and mortality in patients with early-onset alzheimer's disease. Eur Neurol 1996;36(2):103-6
  • Kaufer DI, Cummings JL, Christine D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the neuropsychiatric inventory caregiver distress scale. J Am Geriatr Soc 1998;46(2):210-5
  • Fuh JL, Liu CK, Mega MS, et al. Behavioral disorders and caregivers' reaction in Taiwanese patients with Alzheimer's disease. Int Psychogeriatr 2001;13(1):121-8
  • Donaldson C, Tarrier N, Burns A. Determinants of carer stress in Alzheimer's disease. Int J Geriatr Psychiatry 1998;13(4):248-56
  • Aarsland D, Brønnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007;78(1):36-42
  • Mourik JC, Rosso SM, Niermeijer MF, et al. Frontotemporal dementia: behavioral symptoms and caregiver distress. Dement Geriatr Cogn Disord 2004;18(3-4):299-306
  • Buhr GT, Kuchibhatla M, Clipp EC. Caregivers' reasons for nursing home placement: clues for improving discussions with families prior to the transition. Gerontologist 2006;46(1):52-61
  • Murman DL, Colenda CC. The economic impact of neuropsychiatric symptoms in Alzheimer's disease: can drugs ease the burden [review]? Pharmacoeconomics 2005;23(3):227-42
  • Trihn NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003;289(2):210-6
  • Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004;63(2):214-9
  • Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry 2008;69(3):341-8
  • Alexopoulos GS, Streim J, Carpenter D, et al. Using antipsychotic agents in older patients [review]. J Clin Psychiatry 2004;65(Suppl 2):5-99; discussion 100-102; quiz 103-4
  • Kuehn BM. FDA: antipsychotics risky for elderly. JAMA 2008;300(4):379-80
  • Lanctôt KL, Best TS, Mittmann N, et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry 1998;59(10):550-61; quiz 562-3
  • Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia [review]. Cochrane Database Syst Rev 2002;2:CD002852
  • Devanand DP, Marder K, Michaels KS, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry 1998;155(11):1512-20
  • Allain H, Dautzenberg PH, Maurer K, et al. Double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment. Psychopharmacology (Berl) 2000;148(4):361-6
  • Chan WC, Lam LC, Choy CN, et al. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 2001;16(12):1156-62
  • De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999;53(5):946-55
  • Suh GH, Son HG, Ju YS, et al. A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances. Am J Geriatr Psychiatry 2004;12(5):509-16
  • Tariot PN, Schneider L, Katz IR, et al. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry 2006;14(9):767-76. Erratum in: Am J Geriatr Psychiatry 2006 Nov;14(11):988 [Epub 2006 Aug 11]
  • Schneider LS, Dagerman K, Insel P. Efficacy and adverse effects of atypical antipsychotics for dementia: metanalysis of randomized placebo controlled trials. Am J Geriatr Psychiatry 2006;14:3
  • De Deyn PP, Jeste DV, Swanink R, et al. Aripiprazole for treatment of psychosis in patients with Alzheimer's Disease. J Clin Psychopharm 2005;25(5):463-7
  • Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355:1525-38
  • Sultzer DL, Davis SM, Tariot PN, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 2008;165(7):844-54
  • Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006;1:1-108
  • Glazer WM. Olanzapine and the new generation of antipsychotic agents: patterns of use. J Clin Psychiatry 1997;58(Suppl 10):18-21
  • Jeste DV, Lacro JP, Bailey A, et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999;47(6):716-9
  • Ritsner M, Gibel A, Perelroyzen G, et al. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol 2004;24(6):582-91
  • Stanniland C, Taylor D. Tolerability of atypical antipsychotics. Drug Saf 2000;22(3):195-214
  • Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005;330(7489):445
  • Herrmann N, Mamdani M, Lanctôt KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004;161(6):1113-5
  • Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007;176(5):627-32
  • Center for drug evaluation and research: deaths with antipsychotics in elderly patients with behavioral disturbances. Available from: http://www.fda.gov/cder/drug/advisory/antipsychotics.htm
  • Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART): long-term follow-up of randomized placebo controlled trial. Lancet Neurology 2009;8(2):151-7
  • Ray WA, Chung C, Murray K, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:225-35
  • Michele G. Sullivan. Atypical antipsychotics still used after warning: pattern probably reflects perceptions that clinical benefits outweigh risks for older dementia patients. Clin Psychiatry News. FindArticles.com. 12 Nov 2008
  • Available from: http://www.cbc.ca/health/story/2008/08/25/drug-warnings.html
  • Available from: http://www.nytimes.com/2008/06/24/health/ 24deme.html?_r=1
  • Kales HC, Valenstein M, Kim HM, et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry 2007;164(10):1568-76

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.